# Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration

> **NCT07367282** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Junyeop Lee** · enrollment: 64 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Faricimab Injection [Vabysmo]

## Key facts

- **NCT ID:** NCT07367282
- **Lead sponsor:** Junyeop Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07367282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07367282, "Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT07367282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*